Genmab A/S (NASDAQ:GMAB) Now Covered by Wells Fargo & Company

Equities researchers at Wells Fargo & Company began coverage on shares of Genmab A/S (NASDAQ:GMAB) in a note issued to investors on Monday,Benzinga reports. The firm set an “overweight” rating and a $40.00 price target on the stock. Wells Fargo & Company‘s price target suggests a potential upside of 36.64% from the company’s current price.

Several other brokerages have also recently weighed in on GMAB. Jefferies Financial Group initiated coverage on shares of Genmab A/S in a research note on Tuesday, February 17th. They set a “buy” rating and a $41.50 price target for the company. Wall Street Zen lowered shares of Genmab A/S from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. Morgan Stanley assumed coverage on shares of Genmab A/S in a research note on Monday, February 16th. They set an “equal weight” rating and a $34.00 price objective for the company. HC Wainwright lifted their target price on Genmab A/S from $39.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, February 18th. Finally, Truist Financial reissued a “buy” rating and set a $48.00 price target (down from $49.00) on shares of Genmab A/S in a research report on Thursday, November 6th. Seven investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $40.58.

Genmab A/S Price Performance

Shares of NASDAQ GMAB opened at $29.28 on Monday. The company has a fifty day moving average price of $31.91 and a 200 day moving average price of $30.29. Genmab A/S has a 1-year low of $17.24 and a 1-year high of $35.43. The firm has a market cap of $18.81 billion, a PE ratio of 18.95, a PEG ratio of 1.21 and a beta of 0.94. The company has a current ratio of 2.02, a quick ratio of 2.01 and a debt-to-equity ratio of 0.86.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Tuesday, February 17th. The company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.41). The firm had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.06 billion. Genmab A/S had a net margin of 25.89% and a return on equity of 17.35%. Research analysts predict that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Genmab A/S

Several large investors have recently modified their holdings of the stock. Federated Hermes Inc. bought a new position in Genmab A/S in the 3rd quarter valued at about $12,972,000. JPMorgan Chase & Co. increased its stake in Genmab A/S by 17.0% in the second quarter. JPMorgan Chase & Co. now owns 933,309 shares of the company’s stock valued at $19,282,000 after acquiring an additional 135,814 shares during the last quarter. Oppenheimer Asset Management Inc. raised its position in Genmab A/S by 24.1% during the third quarter. Oppenheimer Asset Management Inc. now owns 315,862 shares of the company’s stock valued at $9,687,000 after purchasing an additional 61,311 shares in the last quarter. Squarepoint Ops LLC lifted its stake in Genmab A/S by 636.3% during the second quarter. Squarepoint Ops LLC now owns 94,233 shares of the company’s stock worth $1,947,000 after purchasing an additional 81,434 shares during the last quarter. Finally, Eagle Global Advisors LLC boosted its holdings in shares of Genmab A/S by 16.3% in the 3rd quarter. Eagle Global Advisors LLC now owns 244,470 shares of the company’s stock valued at $7,498,000 after purchasing an additional 34,175 shares in the last quarter. 7.07% of the stock is owned by institutional investors.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.